Introduction
Colorectal cancer, CRC
COLORECTAL CANCER
Colorectal cancer (CRC) is the third leading cause of mortality in Europe.The phase III ML18147 and VELOUR trials introduced the biological concept that maintaining angiogenesis inhibition after first-line setting is beneficial for patients with mCRC, providing new second-line treatment options for patients with Correlative translational studies, aimed at a better elucidation of the mechanism of action of regorafenib and the identification of predictive biomarkers, will be described separately.